Waive IP Rights & Save Lives

14 Pages Posted: 12 Nov 2021 Last revised: 16 Dec 2021

See all articles by Srividhya Ragavan

Srividhya Ragavan

Texas A&M University School of Law

Date Written: November 9, 2021

Abstract

In October of 2020, when India and South Africa proposed a waiver from certain provisions of the TRIPS agreement, it was meant to increase local manufacturing capacity in these countries although the waiver, in enabling vaccination of populations across the globe, would be critical to normalize global trade. The waiver was proposed as a tool to kick-start prevention, containment and treatment of COVID-19. While there is an imminent need to meet a growing supply-demand gap for all medical products, COVID-19 related products are urgently required in poorer nations to contain the pandemic. The paper hopes to capture the benefits of the waiver and compares it with the existing flexibilities, being compulsory licensing.

Note:
Funding: I did not receive any funds for this paper.

Declaration of Interests: I have no competing interests to declare.

Keywords: trips, patents, pharmaceuticals, covid, access to medicines, IP Waiver, trade, MC2021

Suggested Citation

Ragavan, Srividhya, Waive IP Rights & Save Lives (November 9, 2021). Southviews No. 231, South Centre, 2021, Texas A&M University School of Law Legal Studies Research Paper No. 21-59, Available at SSRN: https://ssrn.com/abstract=3960255 or http://dx.doi.org/10.2139/ssrn.3960255

Srividhya Ragavan (Contact Author)

Texas A&M University School of Law ( email )

1515 Commerce Street
Fort Worth, TX Tarrant County 76102
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
110
Abstract Views
865
Rank
511,155
PlumX Metrics